Dysfunction of the host immune system in cancer patients can be due to a number of factors, including suppression of tumor-associated antigen reactive lymphocytes by CD4 þ CD25 þ regulatory T (Treg) cells. Several studies suggest that Tregs are elevated in cancer patients and that depletion of Tregs may enhance the antitumor immunity of host, but the pathogenic and mechanistic relationship between cancer and Tregs is still unclear. In this report, we show that Tregs are increased in peripheral blood mononuclear cells (PBMCs) from hepatocellular carcinoma (HCC) patients and positively correlate with tumor burden. When PBMCs are co-cultured with human hepatoma cell lines Huh7, HepG2, and Hclone5, CD4 þ CD25 þ -T cell populations increase in frequency and undergo phenotypic and functional changes. CD45RA, CD45RO, CD69, CD62L, GITR, CTLA-4, Ki67, granzyme A, granzyme B, and FOXP3 expression were upregulated in CD4 þ CD25 þ cells after in vitro exposure to HCC cell lines. CD4 þ CD25 þ T cells from PBMCs that were co-cultured with Huh7 cells also have higher suppressor ability compared to that of the CD4 þ CD25 þ T cells from control PBMC. Huh7 culture supernatants appear to promote CD4 þ CD25 þ T-cell proliferation and inhibit CD4 þ CD25 À T-cell proliferation. In conclusion, these results strongly suggest that tumor-related factors not only induce and expand CD4 þ CD25 þ cells, but also enhance their suppressor ability.
Dysfunction of the host immune system in cancer patients can be due to a number of factors, including suppression of tumor-associated antigen reactive lymphocytes by CD4 þ CD25 þ regulatory T (Treg) cells. Several studies suggest that Tregs are elevated in cancer patients and that depletion of Tregs may enhance the antitumor immunity of host, but the pathogenic and mechanistic relationship between cancer and Tregs is still unclear. In this report, we show that Tregs are increased in peripheral blood mononuclear cells (PBMCs) from hepatocellular carcinoma (HCC) patients and positively correlate with tumor burden. When PBMCs are co-cultured with human hepatoma cell lines Huh7, HepG2, and Hclone5, CD4
þ CD25 þ -T cell populations increase in frequency and undergo phenotypic and functional changes. CD45RA, CD45RO, CD69, CD62L, GITR, CTLA-4, Ki67, granzyme A, granzyme B, and FOXP3 expression were upregulated in CD4
þ CD25 þ cells after in vitro exposure to HCC cell lines. CD4 þ CD25 þ T cells from PBMCs that were co-cultured with Huh7 cells also have higher suppressor ability compared to that of the CD4 þ CD25 þ T cells from control PBMC. Huh7 culture supernatants appear to promote CD4 þ CD25 þ T-cell proliferation and inhibit CD4 þ CD25 À T-cell proliferation. In conclusion, these results strongly suggest that tumor-related factors not only induce and expand CD4 þ CD25 þ cells, but also enhance their suppressor ability. Naturally occurring CD4 þ CD25 þ regulatory T cells (Tregs) play a critical role in modulating immune responses by suppressing CD4 þ CD25 À and CD8 þ effector T-cell function. 1 Their depletion leads to more effective immune responses to tumors and infections. [2] [3] [4] In viral hepatitis, recent studies have shown that Tregs are elevated in chronic infection and contribute to viral persistence by suppressing viralspecific T-cell responses. [5] [6] [7] Tregs have also been suggested to impede immune surveillance against cancer. [8] [9] [10] [11] [12] Their inactivation improves tumor-specific immunity and leads to more efficient tumor rejection. [13] [14] [15] Thus, manipulation of Tregs may represent a feasible immunotherapy strategy for cancer.
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and its incidence is increasing owing to the rising prevalence of advanced hepatitis C (HCV) disease. 16 Surgical resection and liver transplantation can be curative when detected early. Unfortunately, the majority of patients are not candidates for these treatments and they have limited options, stressing the importance of a better understanding of HCC pathogenesis. Effector T lymphocytes are important in the control of tumor progression. 17 Lymphocytes that infiltrate tumor have been described in HCC, and their presence after resection indicate a better survival. 18, 19 However, the progression of tumors despite the presence of infiltrating lymphocytes suggests immunologic tolerance generated by tumors. An increase in the Treg population has been observed in both the periphery and tumor microenvironment in patients with cancer. [20] [21] [22] [23] [24] [25] [26] Tumor-infiltrating lymphocytes in HCC appear to contain suppressive Tregs cells that accumulate locally and inhibit tumor-specific immune responses. 27 The recent finding that the telomere length of Tregs is preserved, despite their loss of T-cell receptor circles, provides the first evidence that the increase of Tregs in cancer patients is due to active proliferation rather than redistribution. 28 Nevertheless, the mechanisms involved in the observed expansion of Tregs from tumors remains poorly characterized.
In this study, a higher level of Tregs was found in the periphery of HCC patients, which correlated with the extent of tumor burden. We thus hypothesized that the HCC microenvironment must support Treg expansion and/or deplete CD4 þ CD25 À effector cells to promote immune tolerance. To evaluate this hypothesis, a series of in vitro cultures using supernatants from human HCC cell lines and normal human hepatocytes were performed with peripheral mononuclear,
Our results indicate that HCC culture supernatants promoted expansion of Tregs and enhanced their suppressive function. This supports the hypothesis that the proliferation of Tregs is tumor driven via secretion of soluble factors.
MATERIALS AND METHODS Study Population
One hundred and eight individuals were recruited using a protocol approved by the University of Florida IRB. The study subjects included patients with chronic hepatitis C (CHC) (n ¼ 40), HCV with cirrhosis (n ¼ 15), viral-related HCC (n ¼ 33; 26 with HCV and seven with HBV), non-viralrelated HCC (n ¼ 7), non-HCC liver lesions (hemangiomas, cysts, focal nodular hyperplasia; n ¼ 10) and healthy controls (n ¼ 20). HCC was diagnosed according to the diagnostic guidelines of the AASLD. 29 Clinical data were collected to determine the tumor burden defined as: (1) single lesion o5 cm; (2) two to three lesions o3 cm; (3) multiple lesions not meeting number 2 criteria; (4) vessel involvement; and (5) metastatic disease.
Cell Preparation
Peripheral blood mononuclear cells (PBMCs) were isolated as described previously. 30 CD4 þ T cells were purified from PBMC using the human EasySept CD4
þ Enrichment Cocktail (Stemcell Technologies, Canada). Negatively selected CD4 þ cells were incubated with anti-CD25 microbeads (50 mg/10 8 cells) and selected with the MS column (Miltenyi Biotech, CA, USA) to obtain the CD4 þ CD25 þ and the CD4 þ CD25 À fractions as described previously. 5 The CD4 þ CD25 þ and CD4 þ CD25 À purity was more than 95 and 99%, respectively.
Antibodies
The following monoclonal antibodies were used: CD3-CyC, CD4-APC, CD4-FITC, CD25-PE, CD25-CyC, CD45RA-FITC, CD45RO-FITC, CD69-FITC, CD62L-FITC, CD152-APC, Granzyme A-FITC, Granzyme B-FITC, perforin-FITC, mouse anti-human CD28, mouse anti-human CD3 (BD PharMingen), CD127-PE, Glucocorticoid-induced TNF receptor (GITR)-FITC (R&D System), FOXP3-PE (eBioscience), and Ki67-FITC (Fitzgerald, Flanders, NJ, USA). Isotype-matched antibodies were used.
Cell Culture and Supernatants
The human hepatoma lines, Huh7, HepG2, Hep3B, Hclone5, and normal human hepatocytes (Cellzdirect) were cultured in DEME medium with 20% FBS, 2 mM HEPES, 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin in 5% CO 2 at 371C. The supernatants were collected at 60-80% confluence, after centrifugation at 1200 r.p.m. for 10 min, and then passed through a 0.45 mm filter. Supernatants were stored at À201C.
Transwell Experiments
Six-well transwell chambers with a 0.4 mm porous membrane (Corning-Costar) were used. Briefly, Huh7, HepG2, Hclone5, and normal hepatocytes (5 Â 10 5 /well) were plated underneath the transwell chamber for 4 h, and then 1 ml of PBMC (2.5 Â 10 7 /ml) was added to the inner chamber. After 48 h, PBMCs were harvested and stained for flow cytometry or used to obtain CD4 þ CD25 þ and CD4 þ CD25 À cells.
Flow Cytometry and Labeling
PBMCs were stained with various monoclonal antibodies to determine the frequency and phenotype of Tregs. Briefly, PBMCs were re-suspended at 1 Â 10 7 /ml; blocked with 100 ml human AB serum and then 100 ml (1 Â 10 6 ) cells/tube were incubated with CD3, CD4, CD25, CD69, CD62L, CD45RA, CD45RO, CD127, and GITR for 30 /well) were seeded into 96-well plate in triplicate in 200 ml cRPMI with 5 mg/ml PHA in the presence or absence of Huh7 cell supernatants, the three molecular weight fractions or normal hepatocyte culture supernatants at 371C and 5% CO 2 . After 72 h, each well was pulsed with 1 mCi [ 3 H]thymidine in 20 ml cRPMI for 18 h, harvested, and incorporation measured using a b-scintillation counter. Results were expressed as the mean counts per min (c.p.m.).
A series of co-culture studies with CD4 þ CD25 À 1 Â 10 5 / well cultured with CD4 þ CD25 þ cells at various ratios with PHA (Sigma, MO, USA; 5 mg/ml) or soluble anti-CD3 (10 mg/ ml) plus anti-CD28 (10 mg/ml) were performed. Proliferation was measured after 72 h by [ 
Apoptosis Assay
Apoptosis in the PBMC co-cultured with Huh7 cells was determined using the Vybrants Apoptosis Assay Kit # 3 (Molecular Probes, OR, USA). Briefly, after 48 h of co-culture with Huh7 cells, PBMCs were isolated from the inner chamber and stained with Annexin V and propidium iodide (PI). Apoptosis was assessed by flow cytometry.
FOXP3 Quantitative Real-Time PCR
Total RNA was isolated from PBMCs using TRIzol (Invitrogen, CA, USA) and quantified using the Bio-RAC Smart Spect 3000. cDNA was prepared with high-capacity cDNA archive kit (AB Applied Biosystems, CA, USA). Forckhead/ winged helix transcription factor (FOXP3) levels were quantified using Assay on Demand Gene Expression Products (TaqMan s MGB probes, FAMt dye-labeled) kits and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal control. Primers for FOXP3 and GAPDH were obtained from Applied Biosystems. Amplification was conducted in a total volume of 25 ml in a GeneAmpR 7900 detection system with the following cycling conditions: 2 min at 501C, 10 min at 951C, followed by 40 cycles of 15 s at 951C and 1 min at 601C. Samples were run in duplicate, and their relative expression of FOXP3 was determined by normalizing the expression of each target to GAPDH and then comparing this normalized value to the normalized expression in a reference sample to calculate a fold change value using the delta-delta-Ct method. Results are shown as relative FOXP3 mRNA levels.
Statistical Analysis
Data are expressed as box plots and mean7s.e. Statistical analysis was performed using the Mann-Whitney U-test, and the Spearman correlation with the SPSS 10.1 program. All P values are two-tailed. Differences were considered to be significant if Po0.05.
RESULTS

Frequency, Function, FOXP3 Expression and Correlation Analysis in Patients with HCC
We defined the number of CD4 þ CD25 þ T cells in the peripheral blood of patients with HCC (n ¼ 33), chronic HCV infection (CHC; n ¼ 40), chronic HCV-related cirrhosis (n ¼ 15), and normal healthy controls (n ¼ 20) in an ex vivo fashion with flow cytometry. A significantly higher proportion of CD4 þ CD25 þ cells were found in the periphery of HCC patients (mean, 6.34; s.e.70.50%) when compared to healthy controls (2.0670.19%), CHC (2.9670.10%), and chronic HCVrelated cirrhosis (2.7570.17%) (Po0.001) (Figure 1a) . The presence or absence of cirrhosis did not change the level of CD4 þ CD25 þ T cells in patients with chronic HCV infection. As shown in Figure 1b , the frequency of CD4 þ CD25 þ T cells in viral-related HCC patients (6.3270.50%) and non-viral HCC patients (5.1471.12%) were equivalent, whereas subjects with non-tumor liver lesions had significantly lower levels of CD4 þ CD25 þ T cells (2.3170.18%; P ¼ 0.001).
The transcription factor FOXP3 is a useful marker for the presence of Tregs as it is required for their development and function. 31 Quantitation of FOXP3 by real-time PCR was performed on PBMCs from normal healthy controls, patients with viral hepatitis, and patients with HCC ( Figure 1c To evaluate for any relationship between the frequency of CD4 þ CD25 þ T cells and extent of tumor burden in patients with HCC, correlation analysis was performed. Correlation analysis showed a significant correlation between CD4 þ CD25 þ T-cell frequency and tumor burden in HCC patients (R ¼ 0.489, P ¼ 0.01) (Figure 1e ).
In Vitro Cultures of Hepatoma Cell Lines with Transwelled PBMC
To evaluate further the mechanism of how HCC may upregulate Tregs, we established an in vitro culture system with Huh7 cells, normal hepatocytes, and PBMCs from healthy controls. PBMCs were separated from cells using a transwell chamber to limit their interaction to soluble factors from Huh7 or normal hepatocyte supernatant. Changes in the frequency of the CD4 þ CD25 þ T cells were assessed as a percentage of total CD4 þ T cells by flow cytometry after labeling for CD3, CD4, and CD25 surface expression. These studies showed that supernatants from Huh7 and two additional liver cancer lines (HepG2 and Hclone5) significantly increase the CD4 þ CD25 þ T-cell frequency from baseline levels before culture (mean7s.e.; 6.670.8%) after a 48 h culture period (n ¼ 8: Huh7 14.472.4%; HepG2 14.471.3%; Hclone5 15.172.7%) (all Po0.05, Figure 2a) .
To assess if the observed increase in Treg expansion is specific for cancer cell lines, we performed a series of PBMC co-cultures in the presence of medium alone, normal human hepatocytes or Huh7 cells. The result for a representative culture is shown in Figure 2b . There was a significant increase in the Treg frequency in the PBMC co-cultures with Huh7 cells (Huh7) when compared to the controls of PBMCs before culture (no culture), PBMCs with medium alone (medium) or PBMCs with normal hepatocytes (normal) (n ¼ 5, Huh7 14.0271.93%, vs normal hepatocytes 8.5370.32% P ¼ 0.0026). In contrast to the normal hepatocyte co-cultures, there was a noticeable decrease in the CD4 þ population in Huh7 cell co-cultures during the culture period (49.5971.14 vs 43.3472.75%, P ¼ 0.0162).
Phenotype Analysis of CD4
þ CD25 þ T Cells in PBMCs Co-Cultured with Huh7 The CD4 þ CD25 þ T cells from the transwell culture studies were analyzed for expression of typical cell surface markers, which have been well documented in Treg cells 32 
À proliferation on co-culture and failed to display any significant proliferation when cultured alone (1:0). (e) Correlation analysis between CD4 þ CD25 þ T-cell frequency in viral-related HCC and tumor burden (n ¼ 30).
Tumor burden is defined as the following: 1-single lesion o2 cm; 2-single lesion o5 cm; 3-multiple lesions; 4-vessel involvement; 5-evidence of metastatic disease. A significant correlation is found between CD4 þ CD25 þ T-cell frequency and tumor burden by the nonparametric Spearman rank (R ¼ 0.537; P ¼ 0.002).
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Huh7 cells on the phenotype of Tregs are shown in Figure 3 . The phenotype of the Tregs was also determined in the PBMCs from control cultures that included medium alone and normal human hepatocytes. The frequency of the extracellular and intracellular markers that were stained was statistically equivalent to those observed within the normal PBMCs before co-culture with Huh7 cells (data not shown).
In general, all the markers assessed were upregulated on CD4 þ CD25 þ T cells during co-culture of PBMCs with Huh7. However, those markers whose levels were markedly increased included CD62L (20-126%), GITR (16-31%), CD45RO (71-150%), FOXP3 (13.72-18.86%), and CTLA-4 (CD152, 17-61%). CD69, CD45RA, Ki67, granzyme A, and granzyme B expression were also upregulated but to a lesser degree.
FOXP3 Expression in PBMCs Exposed to Huh7 Supernatant during Cultures
As shown in Figure 4a , there was a twofold increase in FOXP3 expression at the mRNA level from baseline when PBMCs were co-cultured with Huh7 for 48 h. The induction of FOXP3 mRNA expression accompanied the upregulation of CD4 þ CD25 þ T cells and its expression remained stable 72 h into the culture period. A similar induction of FOXP3 mRNA was observed when PBMCs were cultured with increasing concentrations of Huh7 supernatant (Figure 4b ).
Functional Analysis of CD4
þ CD25 þ T Cells from Huh7 and PBMC Cultures CD4 þ CD25 À cells were isolated from fresh PBMCs and stimulated with soluble anti-CD3 and anti-CD28, and cultured with different ratios of CD4 þ CD25 þ T cells derived from fresh PBMCs (before culture) or PBMC from the transwell cultures (after culture) ( Figure 5 ). Isolated CD4 þ CD25 þ cells had no significant proliferative response to anti-CD3 and anti-CD28 stimulation but suppressed the proliferation of target CD4 þ CD25 À T cells. In contrast to the suppression observed by the CD4 þ CD25 þ cells from control PBMCs (1:1; 1385274406 c.p.m.), the suppressor ability of the CD4 þ CD25 þ cells from the PBMC co-cultures with Huh7 was more pronounced (1:1; 43697614 c.p.m.) (P ¼ 0.006).
HCC Supernatants Specifically Suppress PBMC Proliferation in Dose-Dependent Way
We compared the effect of supernatants derived from HCC cell lines (Huh7, HepG2, Hep3B) and normal hepatocytes on PBMC proliferation (Figure 6a 
Huh7 Cells Induce
To evaluate the mechanism by which Huh7 cells alter total CD4 þ cell numbers, the level of CD4 þ cells were followed during the co-cultures of Huh7 with transwelled PBMCs. Although these studies showed an increase in CD4 þ CD25 þ T cells, the total CD4 þ population decreased from 52 to 43% (Figure 2) . Annexin V and PI staining showed this decrease to be related to induction of apoptosis in the CD4 þ T-cell population (Figure 6c ). Proliferation studies showed that the relative increase of CD4 þ CD25 þ T cells was due to proliferation as Huh7 supernatants selectively promoted 
DISCUSSION
The immune system plays a critical role in the surveillance of malignancy and control of tumor progression. In this study, we initially describe an increase in the frequency of Tregs in the peripheral blood of HCC patients, which suggests that they play a central role in tumor immunity. The relative level of FOXP3 mRNA expression along with the functional suppression assay results provide support that the elevated population of CD4 þ CD25 þ T cells identified by flow cytometry in the HCC patients represents a suppressive Treg population. In addition, a significant correlation was found between CD4 þ CD25 þ T-cell frequency and tumor stage in our HCC cohort with higher levels seen in those with vascular involvement and metastatic disease. Recently, a similar difference was found in the prevalence of CD4 þ CD25 þ high T cells between early and advanced disease stages in both gastric cancer and esophageal cancer. 33 Patients with a higher proportion of CD4 þ CD25 þ high T cells had worse survival rates when compared to those patients with a lower proportion of CD4 þ CD25 þ high T cells for both gastric and esophageal cancers. These data provide clinical evidence for the concept that HCC affect the Treg subset promoting tolerance to tumor antigens. Further studies of sufficient sample size are needed to draw valid conclusions regarding the use of Treg frequency as a diagnostic or prognostic tool.
We then used an in vitro HCC transwell model to understand the underlying mechanisms responsible for the upregulation of Tregs observed in our clinical cohort. The in vitro co-cultures of hepatoma cells with PBMCs from healthy donors led to an increase in the number of CD4 þ CD25 þ T cells, suggesting that cancer-derived soluble factors result in the expansion of Tregs. This increase was observed using three different liver cancer cell lines, suggesting that the expansion is not an artifact of a single liver cancer cell line but feature common to hepatoma cell lines. Human CD4 þ CD25 þ T cells consist of a heterogeneous population containing regulatory and nonsuppressive effector/memory T cells. It is the CD4 þ CD25 high T cells that garner the suppressive function characteristic of Tregs. 34 In addition to the discriminating Tregs from activated CD4 þ T cells by the comparatively high expression of CD25, additional markers such as CTLA-4, GITR, and CD45RO show strong expression in the CD4 þ CD25 high T cells, which corresponds to Tregs. The subset of T cells in our cultures with the phenotype CD4 þ CD25 þ express high levels of markers characteristic of Tregs including CD62L, GITR, CD45RO, and CD152. This analysis also found increased CD45RA expression, which is not a typical marker of Tregs. However, a recent study describes the existence of CD45RA
þ Tregs in the periphery of humans that express high levels of FOXP3 and manifests equivalent suppressive activity in vitro when compared to their CD45RO þ Tregs counterparts. 35 Of note, upregulation of FOXP3 mRNA expression occurred during the co-cultures of PBMCs with Huh7 supernatant supporting that the increased CD4 þ CD25 þ T cells in the cultures represent Tregs. Although the presence of these markers is helpful in enumerating and detecting the presence of Tregs, the ultimate test for their presence is demonstrating suppression of target CD4 þ CD25 À T-cell activity. Analysis of the CD4 þ CD25 þ T cells induced by the supernatant of Huh7 co-cultures by proliferation assays reveals that these cells inhibited the proliferative response of CD4 þ CD25 À T cells and induce relative anergy towards TCR stimulation. This functional analysis further confirms that the population of CD4 þ CD25 þ T cells in the co-cultures corresponds to Tregs. An important finding is also the enhancement of suppressor ability by the CD4 þ CD25 þ T cells derived from the cocultures, which indicates that tumor factors may not only increase Treg numbers but also increases their suppressive activity. Some insight into the mechanisms for increased Treg numbers and function can be inferred from our data.
Although prior studies show that CD4 þ CD25 À T cells can be induced into suppressing CD4 þ CD25 þ T cells by peripheral expansion, 36 we were able to demonstrate that the increase in Treg frequency was derived from natural Treg selfexpansion promoted by factors secreted by Huh7 cells and not from conversion of naïve CD4 þ CD25 À T cells. Our data also show that Huh7 supernatants and not normal hepatocyte culture supernatants inhibited PBMC proliferation in dose-dependent manner. The flow cytometry analysis also showed that Huh7 supernatants induced CD4 þ T cells apoptosis while increasing CD4 þ CD25 þ T-cell frequency. þ T cells, CD14 þ monocytes, and both immature and mature dendritic cells, in a CD18 and perforin-dependent manner. 37 Here, we demonstrate that CD4 þ CD25 þ cells express higher levels of granzyme A and granzyme B when cultured with the supernatant from a liver cancer cell line. These findings suggest that the granzyme pathway may be one of the mechanisms that Tregs use in the tumor environment to induce cell-contact dependent suppression and kill effector T cells to control immune responses.
In summary, we found an elevation of Tregs with enhanced suppressive function in the peripheral blood of patients with HCC, which correlated with stage of HCC. Collectively, our clinical and experimental data strongly suggest that HCCderived soluble factor(s) selectively enhances their immunosuppression capabilities and leads to apoptosis of effector T cells. We have begun to isolate the cellular fractions that are responsible for this 'suppressive' effect. A better understanding of the mechanisms of the Treg increase in HCC may allow for future immunotherapeutic and diagnostic opportunities in this population. Hepatocellular carcinoma cell supernatants M Cao et al
